|
|
|
|
Document Preview Exclusive License Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Exclusive License Agreement |
|||
|
Entities: |
BioSante Pharmaceuticals, Inc.; Regents of the University of California; University of California, Los Angeles |
|||
|
Date: |
2002 |
|||
|
Size: |
20KB total |
|||
|
Price: |
$44 |
|||
|
ID: |
#285748 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIALITY UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. A COPY OF THIS AGREEMENT WITH ALL SECTIONS INTACT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Second Amendment to
Exclusive License Agreement
for
Selected Applications of Coated Nanocrystalline Particles
between
The Regents of the University of California
and
BioSante Pharmaceuticals, Inc.
UC Case No 1989-204
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT
FOR SELECTED APPLICATIONS OF COATED NANOCRYSTALLINE PARTICLES
This second amendment (Second Amendment) is effective this 7th day of May, 2001, by and between The Regents of the University of California (The Regents), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and BioSante Pharmaceuticals, Inc. (Licensee), a Wyoming corporation, having a principal place of business at 175 Olde Half Day Road, Suite 247, Lincolnshire, Illinois 60069.
RECITALS
Whereas, Licensee (formerly known as Ben-Abraham Technologies, Inc.) and The Regents entered into a license agreement entitled Exclusive License Agreement for Selected Applications of Coated Nanocrystalline Particles, effective on June 18, 1997, having UC Agreement Control Number 1997-04-0671 (License Agreement), covering licensure to Licensee by The Regents of rights in certain inventions developed by Dr. Nir Kossovsky et al. at the University of California, Los Angeles, and covered by Patent Rights (as defined in the License Agreement);
Whereas, Licensee and The Regents amended the License Agreement effective October 26, 1999, (First Amendment), having UC Agreement Control No. 1997-04-0671A, to include additional terms into the License Agreement and to revise the minimum annual royalties schedule to a more financial and time feasible schedule;
Whereas, Licensee and The Regents amended the License Agreement by notice effective May 25, 2000, having UC Agreement Control No. 1997-04-067lB, to change the name of the companys name from Ben-Abraham Technologies to its current name;
2
Whereas, Licensee has requested The Regents to amend certain provisions in the License Agreement that pertains only to the field of Vaccine Adjuvant and a particular sublicensing arrangement, defined below as Adjuvant Sublicense Agreement, between Licensee and a third party called Corixa Corporation;
Whereas, The Regents is willing to amend the License Agreement to reflect such request.
Now, Therefore, in consideration of the foregoing and the mutual promises and covenants contained herein, the parties hereto agree as follows:
1. Paragraph 1.2 (Definitions) of the License Agreement is deleted in its entirety and replaced with the following:
|
End of Preview |
Home Intelligence Services Subscriptions News About Us